Ho Carole's most recent trade in Denali Therapeutics Inc was a trade of 2,937 Common Stock done at an average price of $13.6 . Disclosure was reported to the exchange on Aug. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 12 Aug 2025 | 2,937 | 217,391 (0%) | 0% | 13.6 | 39,884 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 12 Aug 2025 | 806 | 216,585 (0%) | 0% | 14.6 | 11,800 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 05 Aug 2025 | 44,655 | 220,328 (0%) | 0% | 0.7 | 30,365 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 05 Aug 2025 | 44,655 | 62,500 | - | - | Stock Option (right to buy) | ||
| Royalty Pharma PLC (Class A) | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2025 | 5,806 | 8,558 | - | 0 | Class A Ordinary Shares | |
| Royalty Pharma PLC (Class A) | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2025 | 2,752 | 2,752 | - | 0 | Class A Ordinary Shares | |
| Beam Therapeutics Inc | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 33,662 | 33,662 | - | - | Stock Option (Right to Buy) | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 06 Jan 2025 | 12,255 | 178,580 (0%) | 0% | 20.2 | 247,796 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 06 Jan 2025 | 2,907 | 175,673 (0%) | 0% | 20.8 | 60,495 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 03 Jan 2025 | 162,540 | 162,540 | - | - | Stock Option (right to buy) | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 03 Jan 2025 | 54,180 | 190,835 (0%) | 0% | 0 | Common Stock | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 25 Nov 2024 | 17,845 | 136,655 (0%) | 0% | 0.7 | 12,135 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 25 Nov 2024 | 17,845 | 107,155 | - | - | Stock Option (right to buy) | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 20 Aug 2024 | 14,098 | 124,717 (0%) | 0% | 24.4 | 344,132 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 20 Aug 2024 | 5,907 | 118,810 (0%) | 0% | 25.0 | 147,439 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 20 Aug 2024 | 2,453 | 138,815 (0%) | 0% | 23.8 | 58,357 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 13 Aug 2024 | 2,337 | 141,268 (0%) | 0% | 22.9 | 53,494 | Common Stock | |
| Beam Therapeutics Inc | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 23,114 | 23,114 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Carole Ho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 78,407 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Carole Ho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 39,515 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Carole Ho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 24,222 | 0 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Carole Ho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Apr 2024 | 19,619 | 0 | - | - | Stock Option (Right to Buy) | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 13 Feb 2024 | 2,784 | 145,010 (0%) | 0% | 17.3 | 48,135 | Common Stock | |
| Denali Therapeutics Inc | Ho Carole | Chief Medical Officer | 13 Feb 2024 | 1,405 | 143,605 (0%) | 0% | 17.8 | 24,995 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 10 Jan 2024 | 4,668 | 147,794 (0%) | 0% | 19.0 | 88,785 | Common Stock | |
| Denali Therapeutics Inc | Ho Carole | Chief Medical Officer | 05 Jan 2024 | 9,972 | 198,777 (0%) | 0% | 19.4 | 193,756 | Common Stock | |
| Denali Therapeutics Inc | Ho Carole | Chief Medical Officer | 03 Jan 2024 | 161,160 | 161,160 | - | - | Stock Option (right to buy) | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 03 Jan 2024 | 53,720 | 162,434 (0%) | 0% | 0 | Common Stock | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 23 Aug 2023 | 2,522 | 182,809 (0%) | 0% | 23.2 | 58,561 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 21 Aug 2023 | 2,478 | 185,331 (0%) | 0% | 22.6 | 56,003 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 14 Aug 2023 | 2,768 | 182,809 (0%) | 0% | 23.8 | 65,851 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 10 Aug 2023 | 2,857 | 185,577 (0%) | 0% | 24.2 | 68,997 | Common Stock | |
| Beam Therapeutics Inc | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 16,532 | 16,532 | - | - | Stock Option (Right to Buy) | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 15 Feb 2023 | 1,476 | 182,809 (0%) | 0% | 29.4 | 43,394 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 10 Feb 2023 | 2,548 | 184,285 (0%) | 0% | 30.1 | 76,695 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 10 Feb 2023 | 818 | 179,365 (0%) | 0% | 29.8 | 24,376 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 08 Feb 2023 | 1,521 | 180,183 (0%) | 0% | 30.9 | 46,968 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 09 Jan 2023 | 1,459 | 177,454 (0%) | 0% | 28.5 | 41,552 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 05 Jan 2023 | 2,636 | 180,364 (0%) | 0% | 28.4 | 74,968 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 05 Jan 2023 | 1,451 | 178,913 (0%) | 0% | 28.7 | 41,600 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 03 Jan 2023 | 123,360 | 123,360 | - | - | Stock Option (right to buy) | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 03 Jan 2023 | 41,120 | 138,967 (0%) | 0% | 0 | Common Stock | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 03 Jan 2023 | 2,913 | 175,500 (0%) | 0% | 28.7 | 83,574 | Common Stock | |
| Beam Therapeutics Inc | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 10,391 | 10,391 | - | - | Stock Option (Right to Buy) | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 23 Aug 2022 | 2,424 | 170,663 (0%) | 0% | 32.0 | 77,520 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 19 Aug 2022 | 2,576 | 173,087 (0%) | 0% | 33.2 | 85,575 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 09 Aug 2022 | 22,500 | 110,597 (0%) | 0% | 0 | Common Stock | ||
| Ngm Biopharmaceuticals Inc | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 24,222 | 24,222 | - | - | Stock Option (Right to Buy) | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 11 Feb 2022 | 2,918 | 170,663 (0%) | 0% | 34.7 | 101,284 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 09 Feb 2022 | 1,423 | 166,112 (0%) | 0% | 37.1 | 52,791 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 05 Jan 2022 | 2,845 | 163,285 (0%) | 0% | 44.8 | 127,399 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 03 Jan 2022 | 93,000 | 93,000 | - | - | Stock Option (right to buy) | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 03 Jan 2022 | 31,000 | 107,316 (0%) | 0% | 0 | Common Stock | ||
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 06 Dec 2021 | 1,476 | 76,316 (0%) | 0% | 42.5 | 62,760 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 23 Aug 2021 | 6,143 | 158,630 (0%) | 0% | 48.9 | 300,454 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 19 Aug 2021 | 1,402 | 165,917 (0%) | 0% | 49.3 | 69,133 | Common Stock | |
| Denali Therapeutics Inc | Carole Ho | Chief Medical Officer | 19 Aug 2021 | 1,144 | 164,773 (0%) | 0% | 49.9 | 57,097 | Common Stock | |
| Beam Therapeutics Inc | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 6,877 | 6,877 | - | - | Stock Option (Right to Buy) | |
| Ngm Biopharmaceuticals Inc | Carole Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 19,619 | 19,619 | - | - | Stock Option (Right to Buy) |